Vertex’s KAFTRIO + ivacaftor wins EU nod for cystic fibrosis treatment in children
Vertex Pharmaceuticals has secured approval from the European Commission for the label extension of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor. The oral medicine has been approved